Vantage logo

Eidos chases Pfizer in amyloidosis

Eidos presses ahead in its David and Goliath battle against Pfizer in amyloidosis, but it could have issues with pivotal trial recruitment.

Vantage logo

Esketamine floats past adcom vote

Johnson & Johnson's esketamine should get approved in depression, but a safety plan requiring supervision raises questions about its commercial promise.

Vantage logo

Sanofi does a spring clean

The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.